AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Healthcare Licensing with Focus on Generics: 2019 Analytical Report - ResearchAndMarkets.com

May 8, 2019

DUBLIN--(BUSINESS WIRE)--May 8, 2019--The “Analytical Report for Healthcare Licensing with focus on Generics” report has been added to ResearchAndMarkets.com’s offering.

As one of the oldest sub-sectors of healthcare, generics and its licensing arrangements have evolved in recent times. 50+ healthcare licensing news with focus on Generics are reported and analyzed to provide a snapshot view of the current business trends here.

Analytical data coverage:

  • January 1, 2018 to March 31, 2019 licensing deals and negotiations
  • 50+ worldwide Generics focused healthcare licensing news of companies across North America (53%), Europe (24%), Asia (23%)
  • Small-mid-large cap companies covered - LargeCap (45%), MidCap (31%)
  • Listed and non-listed companies included
  • 4 healthcare sub-sectors covered - Pharmaceuticals (81%), Biotech (8%), Healthcare Services (7%), Medical Devices (1%)
  • 14 medicine groups studied - Neurology (13%), Oncology (13%), Obstetrics & Gynecology (9%)
  • 8+ variables analyzed

User benefits:

  • Immediate access to current global licensing trends in Generics’ businesses
  • Succinct summaries of licensing deals and negotiations held worldwide
  • Quick to-the-point analytical references
  • In-depth updates on wider perspective of Generics business sector
  • Directions to the emerging business prospects

Key analysis in the report:

  • Leading countries in healthcare Generics licensing
  • Most active healthcare sub-sectors in Generics licensing
  • Distribution of Generics licensing deals among market cap groups
  • Comparisons of different medicine groups in Generics licensing
  • Companies currently engaging the most in Generics licensing
  • Dynamics of varied licensing payments arrangements worldwide

Report useful to:

  • Generics healthcare companies seeking licensing opportunities
  • Generics healthcare companies seeking new market base
  • Executives of healthcare companies negotiating licensing in Generics sectors
  • Investors analyzing varied kinds of transaction options for Generics licensing

Key Topics Covered

Introduction

Research Design

Chapter 1: Analysis of healthcare inventions with focus on Generics licensed during the past five quarters

1.1 Number of licensing deals with focus on Generics

1.2 Countries with most licensing deals with focus on Generics

1.3 Healthcare sub-sectors with most licensing deals with focus on Generics

1.4 Market capitalization groups with most licensing deals with focus on Generics

1.5 Medicine groups with most licensing deals with focus on Generics

1.6 Leading companies with most licensing deals with focus on Generics

1.7 Licensing payment arrangements most followed in licensing deals with focus on Generics

Chapter 2: Key licensing deals with focus on Generics during the past five quarters - By type of licensing deal

Chapter 3: Global healthcare inventions with focus on Generics licensed during the past five quarters - By region and company name

Chapter 4: Summary and conclusions

Appendices

Appendix 1 List of companies/institutes covered

a) By region, country and company name

b) By sub-industry, country and company name

c) By market capitalization group, country and company name

d) By medicine group, country and company name

e) By terms of payment, country and company name

Appendix 2 List of non-listed companies covered - By country and company name

Appendix 3 List of not-for-profit institutes covered - By country and institute name

Companies Mentioned

Alphabetical List of Sample 30 Companies/Institutes (of the total 101 companies covered) in the Report:

  • MSN Laboratories Pvt ltd
  • Natco Pharma
  • Neo Health (OTC) Pty Ltd
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Novartis AG
  • Oakrum Pharma, LLC
  • Orifarm Group A/S
  • Panacea Biotec Ltd
  • PDL BioPharma, Inc.
  • Perrigo Animal Health
  • Perrigo Company plc
  • Piedmont Animal Health LLC
  • Prasco Laboratories
  • Reliance Life Sciences Private Lim
  • Resolution Chemicals
  • Rite Aid Corporation
  • Rivopharm SA
  • Sandoz Inc
  • Shilpa Medicare Limited
  • Sol Gel Technologies Ltd
  • Spear Pharmaceuticals, Inc
  • Sumitomo Dainippon Pharma Co Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • SunGen Pharma, LLC
  • Takeda Pharma U.S.A Inc
  • UPMC Health Plan
  • Vectura Group plc
  • Waverley Pharma Inc.
  • West-Ward Pharmaceutical Corp.
  • Zai Lab Limited

For more information about this report visit https://www.researchandmarkets.com/r/lv2awi

View source version on businesswire.com:https://www.businesswire.com/news/home/20190508005633/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Healthcare Services,Generic Drugs

KEYWORD:

INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/08/2019 12:03 PM/DISC: 05/08/2019 12:03 PM

http://www.businesswire.com/news/home/20190508005633/en